Mirati reemerges as potential buyout target with rival Amgen under the microscope

Mirati Therapeutics is once again attracting buyout interest, this time allegedly from Sanofi, according to a report from Bloomberg on Thursday. The biotech’s shares $MRTX surged by roughly 45% in response.

It’s far from the first time Mirati has emerged as a potential…
Click here to view original post